17 OF 25 CONFIRMED 16.4 DAY AVG LEAD TIME · 8 SECTORS
17 of 25 confirmed · 16.4 day avg lead time

Markets reprice fragility after the regime changes. This system identifies it before.

Structural risk research on pharmaceutical, biotechnology, and healthcare systems. Built for institutional healthcare equity analysts, hedge fund PMs, family offices, and wealth managers with healthcare exposure.

Read the methodology 17 of 25 confirmed · 8 sectors · Public log
Prior work endorsed by Gates Foundation · HRH King Charles III · World Health Organization · Google Cloud · MassChallenge · 43North · Lloyds Bank · European Regional Development Fund · Royal Society of Edinburgh
Featured in Forbes · Bloomberg · BBC · Harvard Business Publishing
VERIFIED · TFR
NVDA−$180.0B
META−$150.0B
LLY−$67.1B
NFLX−$43.8B
TSLA−$40.7B
PFE−$3.8B
REGN−$2.6B
NKE−$2.5B
UAL−$2.4B
EL−$0.6B
CAG−$0.4B
ALK−$0.1B
STAPLESSCORE 35+21%
INDUSTRIALSSCORE 40+17%
ENERGYSCORE 42+15%
MATERIALSSCORE 45+12%
TECHSCORE 53FLAT
Proof of signal

17 of 25 confirmed. Nothing hidden.

25 published calls. 17 confirmed. 8 misses. 12 verified company calls across 8 sectors. 5 S&P 500 sector calls in perfect rank order. 1 live sector signal.

Nvidia
Called as most fragile · 1 month prior
Hyperscaler capex concentration and China exposure flagged before the regime shift.
−$180B
Verified
Meta
Called 3 weeks prior
Ad-revenue elasticity and Reality Labs cost dependency identified as transmission drivers.
−$150B
Verified
Eli Lilly
Called 1 month prior
GLP-1 demand normalization and competitive entry threat flagged before the repricing.
−$67.1B
Verified
Netflix
Called #5 most fragile · 1 month prior
Subscriber growth ceiling and content cost inflation under competitive pressure identified.
−$43.8B
Verified
Tesla
Structural fragility call
Demand cycle leverage and margin compression identified before the move.
−$40.7B
Verified
Pfizer
Structural fragility call
Post-COVID revenue cliff with pipeline concentration risk flagged.
−$3.8B
Verified
Regeneron
Called 7 days prior
Dupixent competitive pressure identified as primary transmission driver.
−$2.6B
Verified
Nike
Structural fragility call
Direct-to-consumer model fragility under margin stress identified.
−$2.5B
Verified
United Airlines
Structural fragility call
Capacity and fuel cost sensitivity under softening demand flagged.
−$2.4B
Verified
Estée Lauder
Structural fragility call
China demand collapse and prestige channel dependency identified.
−$0.6B
Verified
Conagra
Structural fragility call
Volume-price tradeoff breaking under consumer trade-down flagged.
−$0.4B
Verified
Alaska Air
Structural fragility call
Regional carrier cost structure fragility under capacity stress.
−$0.1B
Verified
S&P Technology
Sector rank #1 · most fragile
Hyperscaler capex concentration and elevated multiple expansion flagged sector vulnerability.
Score 53
FlatAligned
S&P Materials
Sector rank #2
Commodity cycle dependency and capex intensity identified as transmission drivers.
Score 45
+12%Aligned
S&P Energy
Sector rank #3
Refining margin compression and demand-side cyclical exposure flagged.
Score 42
+15%Aligned
S&P Industrials
Sector rank #4
Capex cycle position and operating leverage identified as resilience drivers.
Score 40
+17%Aligned
S&P Consumer Staples
Sector rank #5 · most resilient
Defensive demand profile and pricing-power durability identified as resilience signals.
Score 35
+21%Aligned
25Published calls total
17Confirmed
8Distinct sectors
5/5S&P sectors · perfect rank order
Methodology

The framework is judgment-based structural research
grounded in 20+ years of operating experience.

17/25

Confirmed calls. Average lead time 16.4 days. All timestamped publicly. All verifiable.

Nine fragility factors integrated into a single analytical view
System-specific structural thresholds with dynamic calibration
Read the full research methodology Open document →
Who built this

Spyridon Ross Tsakas

Founder & President, Tsakas Fragility Radar LLC

20+ years of operating experience across pharmaceutical formulation, drug delivery, biotechnology commercialization, terminal sterilization, contract manufacturing, and capital markets. The Fragility Radar is built on this experience.

First patent granted in 1997, at age 12. First company founded at age 17.

Founder and CEO of Eulysis UK Ltd. Raised $3.88M in venture capital, angel investment, and competitive grants. Acquired at $10.5M valuation via management buyout in 2016. Co-Founder and COO of BioFaran SA, exited via acquisition in 2009 with approximately 4× return on invested capital. Pharmaceutical Segment Leader at Sterigenics, 2021–2025, leading pharmaceutical client engagement across all six terminal sterilization modalities.

Financial Advisor at Merrill Lynch, 2019–2021. Previously held Series 7 and Series 66 credentials. Previously registered as an Investment Advisor Representative.

Doctorate (ABD) in Science, Technology, and Innovation Studies and Master of Science in International Business and Emerging Markets, both from the University of Edinburgh. Faculty appointments at Babson College, Tufts University, Assumption University, Worcester State University, and Florida Gulf Coast University.

Team

Supporting the practice.

Research production, data operations, client delivery, and firm accounting are supported by a dedicated team reporting directly to the Founder.

Role Chief of Staff
Role Chief Data Analyst
Role Chief Marketing Strategist
Role Chief Corporate Accountant
Subscription

One annual subscription. Built for institutional research budgets.

$25,000 per year. No tiers. No upsells. Annual paid in advance.